Urodynamix Announces Completion of Commercial Shipment of uroNIRS 2000 to Medical Measurement Systems B.V.

Urodynamix Technologies Ltd. ("Urodynamix") (TSX VENTURE:URO) today announced
that it has completed its first commercial shipment of uroNIRS 2000 product to
Medical Measurement Systems B.V. ("MMS"), a leading developer and distributor of
medical diagnostic systems for urology, gastroenterology and neurology
headquartered in the Netherlands.  The order valued at $175,000US, will be used
by MMS to spearhead the introduction of the product in the EU.


"The uroNIRS 2000 was very well received at the EAU in Stockholm and we are
delighted to have completed the delivery of our first shipment to our partner
MMS." said Barry Allen, President and CEO of Urodynamix Technologies Ltd. "The
urology market is very interested in NIRS and we are excited about introducing
the user friendly and cost effective device to the global urology office market
where we believe our quick non-invasive diagnostic procedure will have
incredible value."


Along with their dominant presence in product innovation, development and
distribution in the urodynamics markets throughout Europe and Asia, MMS has
strong distribution channels in North America. MMS is a key part of Urodynamix's
expansion strategy to partner with geographic market leaders and capitalize on
significant opportunities globally for uroNIRS technology.


"MMS is excited about introducing the uroNIRS 2000 Bladder Monitor in Europe,
North America and beyond." said Arjen J. de Weerd, President of MMS. "We want to
provide the latest advances in non-invasive diagnostic technology to our global
customer base and the uroNIRS 2000 is one of them."


UroNIRS 2000 is based on a wireless tablet PC with Urodynamix's proprietary
sensor configuration and is compact, portable and specifically designed for ease
of use in the physician's office setting. The non-invasive procedure is used to
confirm the presence of bladder outlet obstruction in men by identifying
patients that have healthy bladder function yet suffer from weak urinary stream,
hesitancy, urinary retention and related symptoms. UroNIRS 2000 is safer,
faster, less expensive and more comfortable than conventional catheter-based
diagnostics for the same condition. Clinical studies have shown that UroNIRS has
an 86% success rate for accurately identifying obstructed male patients, most of
whom are good surgical candidates.


Lower urinary tract symptoms (LUTS) and urinary incontinence (UI) are common in
middle-aged men, with the prevalence of LUTS believed to be as high as 90% in
men aged 50 to 80 years old. The terms describe a range of urinary symptoms that
may be linked with prostate disease or bladder dysfunction. LUTS is most often
associated with an enlarged prostate; however symptoms alone cannot be used to
make an accurate diagnosis or ensure appropriate treatment of the underlying
disease. Expensive, time consuming and painful invasive pressure-flow urodynamic
studies currently offer the only way to differentiate between LUTS caused by
prostatic obstruction and bladder disease. The uro NIRS technology is a
desirable alternative to traditional procedures.


About Medical Measurement Systems B.V.

MMS has been producing urodynamic systems for more than 20 years, including
Solar(TM), Solar SmartFlow(TM) Urodynamics Systems and Flowmaster(TM)
Uroflowmetry products. MMS has an outstanding reputation for product development
and innovation. Their engineers, sales and marketing teams have daily contact
with practicing nurses and physicians all over the world, enabling MMS to
develop diagnostic systems that exactly meet the needs of today's healthcare
professionals.


The main corporate office of MMS is located in Enschede, the Netherlands, where
all products are designed and tested to comply with American and European
medical safety regulations as well as international quality standards.


Global distribution takes place through branch offices in the United States,
Germany and The Netherlands and a worldwide network of highly qualified
distributors who sell and service MMS systems to university, public and private
hospitals in more than 60 countries.


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.
Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024